Use of CFMS inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer

Details for Australian Patent Application No. 2008318854 (hide)

Owner Janssen Pharmaceutica, N.V.

Inventors Manthey, Carl L.

Agent Shelston IP

Pub. Number AU-A-2008318854

PCT Pub. Number WO2009/058801

Priority 60/984,978 02.11.07 US

Filing date 29 October 2008

Wipo publication date 7 May 2009

International Classifications

A61K 31/4439 (2006.01)

A61P 35/04 (2006.01) Antineoplastic agents

Event Publications

20 May 2010 PCT application entered the National Phase

  PCT publication WO2009/058801 Priority application(s): WO2009/058801

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008318855-Hydroalcoholic gel compositions for use with dispensers

2008318851-Orally disintegrated dosage form